Zevra Therapeutics Inc. (ZVRA), which emerged as a commercial-stage company in 2024, is continuing its transformation into a patient-focused leader in rare disease therapeutics. The company's shares touched a 52-week high of $10.03 last week.
The lead product of the company is MIPLYFFA (arimoclomol), an orally delivered treatment for Niemann-Pick disease type C, an ultra-rare, progressive, and neurodegenerative disorder. Approved by the U.S. regulatory agency in September 2024, the drug was commercially launched the following month. The company is expected to seek European Medicines Agency's approval for MIPLYFFA during the second half of this year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.